Development of novel strategies for the treatment of neurogenic cardiovascular disease (CVD) requires a detailed understanding of the long-term controllers of sympathetic nerve activity (SNA). Advances in this field require research at the genomic, cellular, neural network and whole animal levels. The ability of a single laboratory, or institution, to carry out this task is difficult if not impossible. We propose the formation of an inter-institutional Consortium to advance our understanding of the neurogenic basis of CVD with the initial focus on the angiotensin II (Angll)-salt model of hypertension (HTN). There are 3 Specific Aims.
In Aim 1 we will identify brain site(s) that mediate changes in SNA in the Angll-salt model, establish genes in those sites whose expressions change in concert with the HTN, and discern how alterations in excitatory and inhibitory inputs to these sites alter the gene expression profile, SNA, and mean arterial pressure (MAP). We will use viral gene transfer to normalize the gene expression profile, SNA, and MAP in Ang-salt HTN.
In Aim 2 we will establish how Angll and dietary salt cause time-dependent, differential regional SNA and blood flow changes in conscious rats. These studies will establish the importance of capacitance and resistance changes, as well as specific contributions of the renal, splanchnic and hindlimb vascular beds in mediating Angll-salt HTN.
In Aim 3 we will determine how disruption of sensory inputs linked to dietary salt and Angll affect the pathways characterized in Aim 1, and the SNA and cardiovascular response patterns characterized in Aim 2. We feel this integrative approach will provide fertile ground for the development of a greater understanding of the mechanisms that link the nervous system and CVD. We are confident that the inter-institutional collaboration of the Consortium will lead to new perspectives and answers that will ultimately lead to the development of novel genetic-based therapies for neurogenic HTN not achievable using more conventional insular approaches.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL076312-04
Application #
7326827
Study Section
Special Emphasis Panel (ZRG1-CVS-A (90))
Program Officer
Thrasher, Terry N
Project Start
2004-12-05
Project End
2009-11-30
Budget Start
2007-12-15
Budget End
2008-11-30
Support Year
4
Fiscal Year
2008
Total Cost
$1,121,900
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Biology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Fink, Gregory D; Phelps, Jeremiah T (2017) Can we predict the blood pressure response to renal denervation? Auton Neurosci 204:112-118
Asirvatham-Jeyaraj, Ninitha; Fink, Gregory D (2016) Possible role for brain prostanoid pathways in the development of angiotensin II-salt hypertension in rats. Am J Physiol Regul Integr Comp Physiol 311:R232-42
Foss, Jason D; Wainford, Richard D; Engeland, William C et al. (2015) A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin. Am J Physiol Regul Integr Comp Physiol 308:R112-22
Averina, Viktoria A; Othmer, Hans G; Fink, Gregory D et al. (2015) A mathematical model of salt-sensitive hypertension: the neurogenic hypothesis. J Physiol 593:3065-75
Fargali, Samira; Garcia, Angelo L; Sadahiro, Masato et al. (2014) The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure. FASEB J 28:2120-33
Kuroki, Marcos T; Fink, Gregory D; Osborn, John W (2014) Comparison of arterial pressure and plasma ANG II responses to three methods of subcutaneous ANG II administration. Am J Physiol Heart Circ Physiol 307:H670-9
Osborn, John W; Olson, Dalay M; Guzman, Pilar et al. (2014) The neurogenic phase of angiotensin II-salt hypertension is prevented by chronic intracerebroventricular administration of benzamil. Physiol Rep 2:e00245
Veitenheimer, Britta; Osborn, John W (2013) Effects of intrathecal kynurenate on arterial pressure during chronic osmotic stress in conscious rats. Am J Physiol Heart Circ Physiol 304:H303-10
Asirvatham-Jeyaraj, Ninitha; King, Andrew J; Northcott, Carrie A et al. (2013) Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat. Am J Physiol Heart Circ Physiol 305:H1462-70
Foss, Jason D; Fink, Gregory D; Osborn, John W (2013) Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension 61:806-11

Showing the most recent 10 out of 44 publications